Nutriband Inc. (NASDAQ:NTRB - Get Free Report) was the target of a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 262,100 shares, an increase of 377.4% from the January 15th total of 54,900 shares. Based on an average daily volume of 181,900 shares, the days-to-cover ratio is presently 1.4 days. Approximately 5.1% of the company's stock are short sold.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Nutriband stock. Haven Private LLC purchased a new stake in shares of Nutriband Inc. (NASDAQ:NTRB - Free Report) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 11,561 shares of the company's stock, valued at approximately $54,000. Haven Private LLC owned approximately 0.10% of Nutriband at the end of the most recent quarter. 19.70% of the stock is owned by institutional investors.
Nutriband Trading Down 5.9 %
NTRB traded down $0.45 during midday trading on Friday, reaching $7.12. The company had a trading volume of 119,330 shares, compared to its average volume of 475,704. The company has a quick ratio of 4.83, a current ratio of 4.96 and a debt-to-equity ratio of 0.01. Nutriband has a 12-month low of $2.22 and a 12-month high of $11.78. The business has a 50-day moving average price of $5.51 and a two-hundred day moving average price of $5.49.
Nutriband (NASDAQ:NTRB - Get Free Report) last released its earnings results on Tuesday, December 3rd. The company reported ($0.12) earnings per share for the quarter. Nutriband had a negative net margin of 338.51% and a negative return on equity of 54.49%. On average, sell-side analysts forecast that Nutriband will post -0.6 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Separately, Noble Financial assumed coverage on shares of Nutriband in a report on Wednesday, January 22nd. They set an "outperform" rating and a $13.00 price target on the stock.
Get Our Latest Research Report on Nutriband
Nutriband Company Profile
(
Get Free Report)
Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.
Read More
Before you consider Nutriband, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nutriband wasn't on the list.
While Nutriband currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
